Dr David Pook speaks to ecancer about initial results of a phase 1 dose exploration and expansion study of xaluritamig plus abiraterone acetate in patients with mCRPC.

This phase 1 study evaluated xaluritamig, a STEAP1 x CD3 T-cell engager, in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer who have not yet received chemotherapy.

Early results demonstrate encouraging antitumour activity, with strong PSA response rates and objective tumour responses, alongside a median radiographic progression-free survival exceeding 10 months.

Dr Pook notes that the combination showed a manageable safety profile, with expected immune-related events such as cytokine release syndrome and musculoskeletal symptoms, and no treatment-related deaths reported.

He concludes by talking about how these findings fit in to the wider picture of novel therapies in the evolving mCRPC treatment landscape.